K-Ras
K-Ras (KRAS) is a small GTPase that functions as a molecular switch within the RAS/MAPK signaling network, cycling between inactive GDP-bound and active GTP-bound states to regulate cell proliferation, differentiation, and survival[1][2]. Mechanistically, activated KRAS transduces signals from cell-surface receptors to downstream effectors, including the MAPK/ERK and PI3K/AKT pathways, thereby coordinating cellular growth and stress-response programs[1][3]. Oncogenic mutations impair GTP hydrolysis and maintain persistent KRAS signaling, resulting in sustained activation of proliferative pathways that contribute to tumor initiation, progression, and therapeutic resistance across multiple cancer types, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer[2][3][4]. In disease models, mutant KRAS also reshapes the tumor microenvironment through inflammatory and immune-regulatory signaling, further supporting tumor development and immune evasion[3][2]. Compared with the related RAS isoforms HRAS and NRAS, KRAS is the most frequently altered RAS family member in human cancer and accounts for the majority of oncogenic RAS mutations, highlighting its distinct biological and clinical importance[2][5]. For experimental applications, the development of mutation-selective inhibitors, especially KRAS^G12C^ inhibitors, has established a tractable platform for studying KRAS-dependent signaling and therapeutic resistance mechanisms, although resistance remains a major challenge for long-term clinical efficacy[2][5].
References:
- [1]. K-Ras gene information.
- [2]. Huang L, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. [Content Brief]
- [3]. Uniyal P, et al. KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy. Cancers (Basel). 2025 Feb 25;17(5):785. [Content Brief]
- [4]. Suda K, et al. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010 Mar;29(1):49-60. [Content Brief]
- [5]. Riedl JM, et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell. 2026 Mar 9;44(3):471-497. [Content Brief]
-
K-Ras Related Products (283)
Related Products (283)
-
KRAS G12C-IN-72
0 ImagesCat. No.: HY-128414CAS No.: 2326523-41-3KRAS G12C-IN-72 (Example 571) is a KRAS G12C inhibitor. KRAS G12C-IN-72 can be used as a target protein ligand to synthesize PROTACs, such as KRAS degrader-1 (HY-153880). KRAS G12C-IN-72 can be used in cancer research.
-
KRASG12D-IN-4
0 ImagesCat. No.: HY-163488CAS No.: 3034052-35-9KRASG12D-IN-4 (example 38) is a KRasG12D inhibitor with an IC50 of 3.3 nM. KRASG12D-IN-4 inhibits proliferation of pancreatic cancer ASPC-1 cells with an IC50 of 12 nM.
-
KRAS G12D-IN-34
0 ImagesCat. No.: HY-179414CAS No.: 3102130-17-3KRAS G12D-IN-34 (Compound 13) is a KRAS (G12D) inhibitor with IC50 values for KRAS (G12D) and KRAS (WT) of 1.05 nM and 1.59 μM respectively. KRAS G12D-IN-34 can be used for research on non-small cell lung cancer.
-
KRAS G12C inhibitor 53
0 ImagesCat. No.: HY-147634CAS No.: 2761968-93-6KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.
-
KRASG12C ligand-2
0 ImagesCat. No.: HY-175583CAS No.: 2725905-93-9KRASG12C ligand-2 is a KRas ligand used for PROTAC synthesis. KRASG12C ligand-2 serves as the target protein ligand of PROTAC KRAS G12C degrader-2 (HY-153821).
-
RM-041
0 ImagesCat. No.: HY-186086CAS No.: 2953276-07-6RM-041 is a selective, orally active KRASG13C (ON) inhibitor that forms a covalent complex with KRASG13C (ON) and Cyclophilin A. RM-041 blocks the binding of RAS effector proteins via steric hindrance, and then covalently binds to Cys-13 to form an irreversible inhibitory complex, thereby inhibiting the proliferation of KRASG13C mutant cancer cells. RM-041 induces regression of KRASG13C tumors in cellular and xenograft tumor models. RM-041 exerts a synergistic effect when combined with upstream node inhibitors (such as SHP2 inhibitors). RM-041 can be used for the research of non-small cell lung cancer.
-
KRAS-IN-54
0 ImagesCat. No.: HY-181704CAS No.: 3084918-70-4KRAS-IN-54 is a macrocyclic KRAS inhibitor. KRAS-IN-54 exhibits activity against cell viability and pERK inhibition in cells with KRASG12D and KRASG13D mutations. KRAS-IN-54 can be used in the research of KRAS-mutant cancers, including pancreatic adenocarcinoma, colorectal cancer, non-small cell lung cancer, esophageal cancer, gallbladder cancer, melanoma, ovarian cancer and endometrial cancer.
-
KRAS-IN-5
0 ImagesCat. No.: HY-174261CAS No.: 3082412-00-5KRAS-IN-5 (Compound Ex 6) is an orally active and selective inhibitor targeting KRAS mutants (including KRASG12D, KRASG12V, KRASWT) with a GNE IC50 value of 1.3 nM against KRASG12D. KRAS-IN-5 blocks tumor cell proliferation by inhibiting KRAS-mediated signaling pathways (e.g., reducing ERK phosphorylation). KRAS-IN-5 is promising for research of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, lung cancer.
-
YN14 (mixture of diastereomers)
0 ImagesCat. No.: HY-155356ACAS No.: 3053689-54-3YN14 mixture of diastereomers is a diastereomer mixture of YN14 (HY-155356). YN14 is a KRASG12C PROTAC degrader that recruits E3 ubiquitin ligase to induce the polyubiquitination and proteasomal degradation of KRASG12C. YN14 induces tumor cell apoptosis, cell cycle arrest, and cell migration inhibition. YN14 exhibits in vivo antitumor proliferative activity in tumor cell xenograft nude mice. YN14 can be used in cancer-related research.
-
KRASG12C IN-16
0 ImagesCat. No.: HY-168919KRASG12C IN-16 (Compound SK-17) is a selective, covalent and an orally active KRASG12C inhibitor. KRASG12C IN-16 induces Apoptosis. KRASG12C IN-16 effectively prevents the activation of MAPK and PI3K/mTOR signaling pathways. KRASG12C IN-16 displays anti-tumor activity against pancreatic cancer.
-
KRAS inhibitor-26
0 ImagesCat. No.: HY-159476CAS No.: 3030576-80-5KRAS inhibitor-26 is a KRas protein inhibitor with activity against dysregulated and mutant KRASG12C proteins. KRAS inhibitor-26 modulates KRAS-mediated signaling pathways. KRAS inhibitor-26 can be used for the research of cancer.
-
KRAS inhibitor-25
0 ImagesCat. No.: HY-159475CAS No.: 3030577-05-7KRAS inhibitor-25 (compound 151a) is a pyridopyrimidine KRAS inhibitor, with an IC50 of < 100 nM against KRas G12V, KRas WT and KRas G12R.
-
SOS1-IN-28
0 ImagesCat. No.: HY-184586SOS1-IN-28 is an orally active, blood-brain barrier permeable SOS1 inhibitor with an IC50 value of 0.11 μM. SOS1-IN-28 disrupts the SOS1: KRAS protein-protein interaction, with an IC50 of 0.29 μM for the KRAS-RAF interaction. SOS1-IN-28 blocks GTP loading of KRAS, inhibits RAS-MAPK pathway activity, and reduces cancer cell proliferation. SOS1-IN-28 can be used for the research of KRASG12C-mutant lung cancer.
-
DCAI hydrochloride
0 ImagesCat. No.: HY-118692ACAS No.: 1049742-84-8DCAI hydrochloride is a KRas inhibitor with a Kd value of 1.1 mM. DCAI hydrochloride directly binds to the Ras protein and competitively inhibits SOS-mediated nucleotide release (IC50 = 155 μM) and exchange reaction (IC50 = 342 μM). DCAI hydrochloride binds to the pocket at the Ras-SOS interface and blocks the formation of the Ras-SOS complex intermediate by impeding salt bridge formation through steric hindrance and the induction of Ras conformational changes. DCAI hydrochloride is used in the study of wild-type and mutant Ras tumors.
-
KRAS G12C inhibitor 62
0 ImagesCat. No.: HY-157067CAS No.: 2658588-10-2KRAS G12C inhibitor 62 is a KRAS G12C inhibitor. KRAS G12C inhibitor 62 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021121367A1).
-
BJP-06-005-3
0 ImagesCat. No.: HY-187694CAS No.: 2400958-08-7BJP-06-005-3 is a selective Pin1 inhibitor with a Ki value of 48 nM. BJP-06-005-3 induces the degradation of mutant KRAS. BJP-06-005-3 inhibits pancreatic ductal adenocarcinoma via the Pin1-mediated pathway. BJP-06-005-3 is used in studies related to KRAS-mutant pancreatic ductal adenocarcinoma.
-
KRAS G12C-IN-80
0 ImagesCat. No.: HY-184821CAS No.: 2925468-57-9KRAS G12C-IN-80 is an orally active KRASG12C inhibitor. KRAS G12C-IN-80 exhibits antitumor activity in vivo. KRAS G12C-IN-80 can be used in research related to non-small cell lung cancer.
